Jinyu Bio-technology Co., Ltd. (SHSE: 600201)
Health Care · Biotechnology · CN
CN¥12.65
-6.50% today · +40.9% 1Y
Jinyu Bio-technology Co., Ltd. (SHSE: 600201) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.05B and employs 1,881 people.
Over the last twelve months the share price has gained 40.9%, trading between 7.99 and 19.00.
Tweenvest scores Jinyu Bio-technology Co., Ltd. across four factors: quality 72/100, value 13/100, growth 0/100, dividend 38/100. Its strongest factor is quality.
600201 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.05B
- Revenue (TTM)
- $225.72M
- P/E
- 99.35
- EPS
- 0.13
- Dividend yield
- 0.29%
- Beta (5Y)
- 0.67
- 52-week high
- CN¥19.00
- 52-week low
- CN¥7.99
- Avg volume (3M)
- —
- Shares outstanding
- 1.09B
- Employees
- 1,881
- Next earnings
- —
About Jinyu Bio-technology Co., Ltd.
Based in Hohhot, China, Jinyu Bio-technology Co., Ltd. is a Chinese firm specializing in the development, production, and commercialization of biological products for animal health. Established in 1992, the company provides crucial vaccines designed to combat diseases such as foot-and-mouth disease, highly pathogenic avian influenza, brucellosis, rabies, and swine fever. These vital immunizations are supplied for a broad spectrum of animals, including pigs, poultry, ruminants, and companion pets. The entity formally adopted its current name, Jinyu Bio-technology Co., Ltd., in December 2015, having previously operated as Inner Mongolia Jinyu Group Co., Ltd.
- ISIN
- CNE000000Y37
- Founded
- 1992
- Listed since
- Jan 15, 1999
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.